​

CytomX Therapeutics Ownership | Who Owns CytomX Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

CytomX Therapeutics Ownership Summary

CytomX Therapeutics is owned by 54.45% institutional investors, 1.12% insiders, and 44.43% retail investors. Tang capital management is the largest institutional shareholder, holding 8.59% of CTMX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.07% of its assets in CytomX Therapeutics shares.

CTMX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCytomX Therapeutics54.45%1.12%44.43%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Tang capital management7.31M8.59%$7.53M
Bvf inc/il5.23M6.14%$5.39M
Vanguard group5.16M6.07%$5.32M
Prosight management, lp3.90M4.59%$4.02M
Millennium management3.22M3.79%$3.32M
Acadian asset management3.14M3.69%$3.23M
Point72 asset management2.65M3.11%$2.73M
Jacobs levy equity management1.51M1.84%$1.84M
Schonfeld strategic advisors1.38M1.62%$1.42M
Renaissance1.35M1.58%$1.39M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Prosight management, lp3.90M1.11%$4.02M
Tang capital management7.31M0.50%$7.53M
Congress park capital964.59K0.36%$993.53K
Bvf inc/il5.23M0.18%$5.39M
Altium capital management lp467.49K0.14%$481.52K
Formidable asset management258.00K0.05%$314.76K
Velan capital investment management lp35.00K0.03%$36.05K
Forefront analytics64.26K0.03%$66.19K
Adar1 capital management145.04K0.03%$149.39K
Laurion capital management lp1.25M0.02%$1.29M

Top Buyers

HolderShares% AssetsChange
Point72 asset management2.65M0.01%2.65M
Jacobs levy equity management1.51M0.01%977.78K
Prosight management, lp3.90M1.11%882.89K
Jpmorgan chase811.63K0.00%811.35K
Millennium management3.22M0.00%660.76K

Top Sellers

HolderShares% AssetsChange
Janus henderson group---4.81M
Orbimed advisors---3.54M
Adage capital partners gp---3.00M
Sio capital management---1.60M
Rtw investments, lp---1.20M

New Positions

HolderShares% AssetsChangeValue
Point72 asset management2.65M0.01%2.65M$2.73M
Vanguard personalized indexing management36.99K0.00%36.99K$38.10K
Velan capital investment management lp35.00K0.03%35.00K$36.05K
Algert global33.57K0.00%33.57K$35.00K
Traphagen investment advisors30.50K0.00%30.50K$31.41K

Sold Out

HolderChange
Innealta capital-2.00
Federated hermes-117.00
Old point trust & financial services n a-250.00
Wells fargo & company/mn-524.00
Macquarie group-1.13K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202470-2.78%46,332,988-9.49%541.50%3421.43%21-12.50%
Sep 30, 202470-9.09%50,859,2220.34%591.57%27-35.71%23-
Jun 30, 202477-15.38%50,687,25714.42%611.72%42-8.70%23-8.00%
Mar 31, 20249133.82%44,300,46236.07%603.69%4691.67%2525.00%
Dec 31, 2023687.94%32,557,3140.67%401.71%2471.43%20-20.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.46M3.07%-
Vanguard US Total Market Shares ETF2.46M3.07%-
Vanguard Institutional Extnd Mkt Idx Tr981.49K1.23%-
Vanguard Explorer Inv820.46K1.05%-
Vanguard Strategic Small-Cap Equity Inv555.12K0.71%-
Acadian Global Small-Cap Equity CIT Cl A487.90K0.61%-
Fidelity Extended Market Index431.82K0.54%-2.75K
Formidable ETF353.84K0.44%-
Vanguard VIF Small Co Gr235.81K0.30%-
Candriam Global Equities Oncology210.00K0.27%210.00K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 18, 2025McCarthy Sean A. CEOSell$22.56K
Mar 18, 2025Ogden Christopher Chief Financial OfficerSell$5.12K
Mar 18, 2025Chu Yu-Waye Chief Medical OfficerSell$2.41K
Mar 18, 2025ROWLAND LLOYD A General CounselSell$6.11K
Mar 18, 2025BELVIN MARCIA SVP, Chief Scientific OfficerSell$11.69K

Insider Transactions Trends

DateBuySell
2025 Q1-5
2024 Q3-5
2024 Q2--
2024 Q1-5
2023 Q4-5

CTMX Ownership FAQ

Who Owns CytomX Therapeutics?

CytomX Therapeutics shareholders are primarily institutional investors at 54.45%, followed by 1.12% insiders and 44.43% retail investors. The average institutional ownership in CytomX Therapeutics's industry, Biotech Stocks , is 68.48%, which CytomX Therapeutics falls below.

Who owns the most shares of CytomX Therapeutics?

CytomX Therapeutics’s largest shareholders are Tang capital management (7.31M shares, 8.59%), Bvf inc/il (5.23M shares, 6.14%), and Vanguard group (5.16M shares, 6.07%). Together, they hold 20.80% of CytomX Therapeutics’s total shares outstanding.

Does Blackrock own CytomX Therapeutics?

BlackRock is not among the top 10 institutional shareholders of CytomX Therapeutics.

Who is CytomX Therapeutics’s biggest shareholder by percentage of total assets invested?

Prosight management, lp is CytomX Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.11% of its assets in 3.9M CytomX Therapeutics shares, valued at 4.02M$.

Who is the top mutual fund holder of CytomX Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of CytomX Therapeutics shares, with 3.07% of its total shares outstanding invested in 2.46M CytomX Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools